China Conditionally Approves Ifupinostat for Relapsed/Refractory Lymphoma Treatment

Chinese authorities have granted conditional approval for Ifupinostat, also known as Betlin, as a monotherapy for adults with relapsed or refractory diffuse large B-cell lymphoma. This first-in-class medication targets two key mechanisms of tumor growth. The approval offers a new treatment option for patients with this challenging form of cancer.